News
PeptiDream Announces Preclinical Results Demonstrating Efficacy of Oral Myostatin Inhibitors in Preventing Loss of Lean Mass Associated with Semaglutide Treatment December 12, 2024 08:00 AM ...
Scholar Rock’s myostatin blocker has shown its efficacy in spinal muscular atrophy, and the 28-year-old myostatin field is now looking to muscle in on obesity.
--Elevai Biosciences Inc., a subsidiary of Elevai Labs Inc., today released encouraging past preclinical data from 2022 for EL-32, a pioneering dual-action blocker targeting myostatin and activin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results